<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04544696</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL20_0433</org_study_id>
    <nct_id>NCT04544696</nct_id>
  </id_info>
  <brief_title>Pharmacist for Detecting Opioid Misuse</brief_title>
  <official_title>Pharmacists in Detecting Opioid Misuse Using the Prescription Opioid Misuse Index (POMI): Survey in a Region in the South of France, Occitanie-Est</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Opioid use is increasing in Western countries and is associated with harms as&#xD;
      hospitalization, addiction and deaths(1). Community pharmacists interact frequently with&#xD;
      patients, giving them the opportunity to identify and prevent the risk of prescribed opioid&#xD;
      misuse. The purpose of this study was therefore to assess the risk of prescribed opioids&#xD;
      misuse in ambulatory patients with chronic non-cancer pain (CNCP) seen in community&#xD;
      pharmacies.&#xD;
&#xD;
      Method: A questionnaire (including the Prescription Opioid Misuse POMI(2)) have been proposed&#xD;
      to patients with opioid prescription by pharmacy students, in 86 pharmacies of Occitanie-Est,&#xD;
      in April 2019. Eligible patients were adults with CNCP that consented to participate.&#xD;
&#xD;
      A total of 414 patients (62.4% women, mean age 58 ± 16.00) have been included. The main pains&#xD;
      were spinal (37.3%) and osteoarticular (33.1%). The median visual analog scale (VAS) was 7&#xD;
      [IQR25-75: 5-8]. The prescribed opioids are mainly weak opioids (73.2%): paracetamol/tramadol&#xD;
      (35%), paracetamol/codeine (17.4%), paracetamol/opium (16.8%). Strong opioids (32.6%) were&#xD;
      oxycodone (11.95%), fentanyl (9%), and morphine (9%). The median morphine milligram&#xD;
      equivalent (MME) was 40 mg/day [IQR25-75: 20-80].&#xD;
&#xD;
      POMI score was superior to 2/6 in 45.4% and superior to 4 in 16%. The main positive question&#xD;
      were feel high (40.3%), take the opioid more often (39.3%), take more medication (36.6), and&#xD;
      need to early renew opioid medication earlier (30.8%).&#xD;
&#xD;
      Patients with POMI score &gt; 4 were younger (49 years versus 55.9; p&lt;0.01), more urban (78.1%&#xD;
      versus 69.2%; p=0.03), had higher VAS (7.3 versus 6.2; p&lt;0.01), received higher median MME&#xD;
      (112 mg versus 64.9 mg; p&lt;0.01), and consumed more strong opioid (45.3% versus 27.3%;&#xD;
      p=0.04).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 17, 2019</start_date>
  <completion_date type="Actual">June 1, 2019</completion_date>
  <primary_completion_date type="Actual">June 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Patients with POMI test &quot;Prescribed Opioid Misuse Index&quot;&gt; 2</measure>
    <time_frame>1 day</time_frame>
    <description>Patients with POMI test &gt; 2 A score &gt;2, may be associated with a risk of misuse of opioid medication. It is recommended to discuss this with the physician</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">414</enrollment>
  <condition>Chronic Non Cancer Pain</condition>
  <arm_group>
    <arm_group_label>Patients with chronic non cancer pain</arm_group_label>
    <description>Patients with chronic non cancer pain, treated with opioids and having completed the POMi questionnaire</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with chronic non cancer pain&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  -Collection of the questionnaire in a community pharmacy of the area of investigation&#xD;
             East-Occitania)&#xD;
&#xD;
          -  Patient over 18 years of age&#xD;
&#xD;
          -  Suffering from pain (CNCP) (&gt; 3 months old)&#xD;
&#xD;
          -  Treated with weak or strong opioids&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Collection of the questionnaire in a community pharmacy outside Eastern Occitania&#xD;
&#xD;
          -  Patient under 18 years of age&#xD;
&#xD;
          -  Suffering from acute pain (&lt; 3 months old) or cancerous pain&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hélène Peyrière, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>UH Montpellier</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Uhmontpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34290</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 3, 2020</study_first_submitted>
  <study_first_submitted_qc>September 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2020</study_first_posted>
  <last_update_submitted>September 10, 2020</last_update_submitted>
  <last_update_submitted_qc>September 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Opioid</keyword>
  <keyword>Misuse</keyword>
  <keyword>Community pharmacy</keyword>
  <keyword>POMI test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

